Juno Therapeutics

What is Juno Therapeutics?

Juno Therapeutics operates as a clinical-stage company that focuses on developing a broad pipeline of innovative cancer immunotherapies. They bring together the expertise of three leading cancer centers - Fred Hutchinson Cancer Research Center, Memorial Sloan-Kettering Cancer Center, and Seattle Children's Research Institute to revolutionize cancer treatment.

By harnessing the body's own immune system to fight cancer, Juno aims to develop two distinct, yet complementary platforms: Chimeric Antigen Receptor (CAR) technology and T-cell Receptor (TCR) technology. With one of the largest Series A investments in biotech history, Juno has made significant strides in advancing these therapies.

Investing solely in Series A ventures, they have a clearly defined investment profile with both minimum and maximum fund investments pegged at $47,000,000, signaling a focused and substantial commitment to their selected ventures. Juno's mission is integrated into the larger framework of the global biopharmaceutical company Bristol Myers Squibb.

The acquisition by Bristol Myers Squibb positions Juno within an expansive portfolio that extends beyond oncology, covering areas such as hematology, immunology, cardiovascular disease, and fibrosis. Together, they work towards transforming patient lives through science and have been involved in crucial advancements in the industry such as the latest FDA approvals for oncology treatments and the development of new therapy administration methods.

Shareholders and investors are engaged through detailed financial reporting, regular updates on investments, and the potential for long-term growth through pioneering treatments. The firm's dedication to medical research, support for researchers with grants and resources, initiatives to drive STEM education, and fostering diversity in science underscores their commitment to innovation and societal impact